The Alzheimer’s Disease Diagnostic Market Insights & Analysis by Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), Diagnostic test (Genetic testing, Neurological exam, Mini-mental state exam (MMSE), Brain imaging), End Users (Clinics, Hospitals, Diagnostic Centers ) - Forecast Till 2032
Alzheimer’s refers to a neurological disorder that causes...
The Alzheimer’s Disease Diagnostic Market Insights & Analysis by Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), Diagnostic test (Genetic testing, Neurological exam, Mini-mental state exam (MMSE), Brain imaging), End Users (Clinics, Hospitals, Diagnostic Centers ) - Forecast Till 2032
Alzheimer’s refers to a neurological disorder that causes...
The 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 has emerged as a cornerstone for unveiling groundbreaking research, therapeutic advancements, and collaborative efforts in Alzheimer’s disease treatment. With Alzheimer’s being a leading cause of dementia globally, the conference spotlights pivotal clinical trials, innovative therapies, and the...
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia, affecting millions of people worldwide. It is characterized by cognitive decline, memory loss, and behavioral changes that worsen over time. The increasing prevalence of Alzheimer's, driven by an aging global population and advances in diagnostics, has spurred substantial...